Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 6/2019

01-06-2019 | Breast Oncology

Response to: “Intact Excision of Breast Lesions Using BLES™: Is There a Clinical Indication Yet?”

Author: Pat Whitworth, MD

Published in: Annals of Surgical Oncology | Issue 6/2019

Login to get access

Excerpt

In response to our article1, in her editorial2 Yao states that a second procedure was needed to achieve clear margins in 27% of patients: “Of 124 cancer patients, 55% had clear margins after undergoing a biopsy with the BLES device, 27% underwent another procedure with the BLES device to establish negative margins”. She repeats this error when summarizing the results in cancer patients: “In the current study, 55% of cancerous lesions (DCIS and invasive carcinoma) had complete excision, with one procedure using the BLES device, and 45% of patients had to undergo another procedure, either with the BLES device or surgical excision”. …
Literature
1.
Whitworth P, Schonholz S, Phillips R, et al. Minimally invasive intact excision of high-risk breast lesions and small breast cancers: the Intact Percutaneous Excision (IPEX) Registry. Ann Surg Oncol. 2019;26(4):954–60.CrossRefPubMed
2.
Yao K. Intact excision of breast lesions using BLES™: Is there a clinical indication yet? Ann Surg Oncol. 2019;26(4):933–5.CrossRefPubMed
Metadata
Title
Response to: “Intact Excision of Breast Lesions Using BLES™: Is There a Clinical Indication Yet?”
Author
Pat Whitworth, MD
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 6/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07317-8

Other articles of this Issue 6/2019

Annals of Surgical Oncology 6/2019 Go to the issue

Gastrointestinal Oncology

The Relevance of Serosal Exposure Without Nodal Metastasis in Resectional Gastric Cancer

Thoracic Oncology

Prognostic Impact of Tumor Spread Through Air Spaces in Sublobar Resection for 1A Lung Adenocarcinoma Patients

Hepatobiliary Tumors

Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer

Health Services Research and Global Oncology

Global Forum of Cancer Surgeons: Perspectives on Barriers to Surgical Care for Cancer Patients and Potential Solutions

Gastrointestinal Oncology

Letter to the Editor Regarding ‘What is the Best Option Between Primary Diverting Stoma or Endoscopic Stent as a Bridge to Surgery with a Curative Intent for Obstructed Left Colon Cancer? Results from a Propensity Score Analysis of the French Surgical Association Multicenter Cohort of 518 Patients’

Gastrointestinal Oncology

Does Noncompliance in Lymph Node Dissection Affect Oncological Efficacy in Gastric Cancer Patients Undergoing Radical Gastrectomy?